Full Text Journal Articles by
Author Richard M Goldberg

Advertisement

Find full text journal articles






Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology.

Richard M Goldberg, Richard Adams, Marc Buyse, Cathy Eng, Axel Grothey, Thierry André, Alberto F Sobrero, Stuart M Lichtman, Al B Benson, Cornelis J A Punt, Tim Maughan, Tomasz Burzykowski, Dirkje Sommeijer, Everardo D Saad, Qian Shi, Elisabeth Coart, Benoist Chibaudel, Miriam Koopman, Hans-Joachim Schmoll, Takayuki Yoshino, Julien Taieb, Niall C Tebbutt, John Zalcberg, Josep Tabernero, Eric Van Cutsem, Alastair Matheson, Aimery de Gramont,

Meta-analysis based upon individual participant data (IPD) is a powerful methodology for synthesizing evidence by combining information drawn from multiple trials. Hitherto, its principal application has been in questions of clinical management, but an increasingly important use is in clarifying trials methodology, for instance in the selection of endpoints, as ... Read more >>

J Natl Cancer Inst (Journal of the National Cancer Institute)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Association of Homologous Recombination-DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers.

Michael Cerniglia, Joanne Xiu, Axel Grothey, Michael J Pishvaian, Yasmine Baca, Jimmy J Hwang, John L Marshall, Ari M VanderWalde, Anthony F Shields, Heinz-Josef Lenz, W Michael Korn, Mohamed Salem, Philip A Philip, Richard M Goldberg, Jia Zeng, Sunnie S Kim,

The prevalence of homologous recombination-DNA damage response (HR-DDR) genetic alterations is of therapeutic interest in gastroesophageal cancers. This study is a comprehensive assessment of HR-DDR mutation prevalence across gastroesophageal adenocarcinomas and squamous cell carcinomas. Here we investigate the association of HR-DDR mutations with known predictors for immune-checkpoint inhibition [deficiency in ... Read more >>

Mol Cancer Ther (Molecular cancer therapeutics)
[2022, 21(1):227-236]

Cited: 0 times

View full text PDF listing >>



Advertisement

Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients.

Alberto Puccini, Andreas Seeber, Joanne Xiu, Richard M Goldberg, Davide Soldato, Axel Grothey, Anthony F Shields, Mohamed E Salem, Francesca Battaglin, Martin D Berger, Wafik S El-Deiry, Ryuma Tokunaga, Madiha Naseem, Wu Zhang, Sukeshi Patel Arora, Moh'd M Khushman, Michael J Hall, Philip A Philip, John L Marshall, W Michael Korn, Heinz-Josef Lenz,

Lymph nodes (LNs) and distant metastases can arise from independent subclones of the primary tumor. Herein, we characterized the molecular landscape and the differences between LNs, distant metastases and primary colorectal cancers (CRCs). Samples were analyzed using next generation sequencing (NGS, MiSeq on 47 genes, NextSeq on 592 genes) and ... Read more >>

NPJ Precis Oncol (NPJ precision oncology)
[2021, 5(1):95]

Cited: 0 times

View full text PDF listing >>



Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer.

Hiroyuki Arai, Andrew Elliott, Joshua Millstein, Joanne Xiu, Fang-Shu Ou, Federico Innocenti, Jingyuan Wang, Francesca Battaglin, Priya Jayachandran, Natsuko Kawanishi, Shivani Soni, Wu Zhang, Davendra Sohal, Richard M Goldberg, Michael J Hall, Aaron J Scott, Mohd Khushman, Jimmy J Hwang, Emil Lou, Benjamin A Weinberg, Albert Craig Lockhart, Anthony Frank Shields, Jim P Abraham, Daniel Magee, Phillip Stafford, Jian Zhang, Alan P Venook, W Michael Korn, Heinz-Josef Lenz,

Loss-of-function alterations of Neurofibromin 1 (NF1) activate RAS, a driver of colorectal cancer. However, the clinical implications of NF1 alterations are largely unknown. We performed a comprehensive molecular profiling of NF1-mutant colorectal cancer using data from 8150 patients included in a dataset of commercial CLIA-certified laboratory (Caris Life Sciences). In ... Read more >>

Oncogene (Oncogene)
[2022, 41(2):260-267]

Cited: 0 times

View full text PDF listing >>



Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database.

Zhaohui Jin, Jesse G Dixon, Jack M Fiskum, Hiral D Parekh, Frank A Sinicrope, Greg Yothers, Carmen J Allegra, Norman Wolmark, Daniel Haller, Hans-Joachim Schmoll, Aimery de Gramont, Rachel Kerr, Julien Taieb, Eric Van Cutsem, Christopher Tweleves, Michael O'Connell, Leonard B Saltz, Sotaro Sadahiro, Charles D Blanke, Naohiro Tomita, Jean-Francois Seitz, Charles Erlichman, Takayuki Yoshino, Takeharu Yamanaka, Silvia Marsoni, Thierry Andre, Amit Mahipal, Richard M Goldberg, Thomas J George, Qian Shi,

<h4>Background</h4>Colon cancer (CC) incidence in young adults (age 20-49 years), termed early-onset CC (EO-CC), is increasing.<h4>Methods</h4>Individual patient data on 35 713 subjects with stage III colon cancer from 25 randomized studies in the Adjuvant Colon Cancer ENdpoint database were pooled. The distributions of demographics, clinicopathological features, biomarker status, and outcome data were ... Read more >>

J Natl Cancer Inst (Journal of the National Cancer Institute)
[2021, :]

Cited: 1 time

View full text PDF listing >>



Association of Adiponectin and Vitamin D With Tumor Infiltrating Lymphocytes and Survival in Stage III Colon Cancer.

Frank A Sinicrope, Qian Shi, Thomas C Smyrk, Richard M Goldberg, Steven J Cohen, Sharlene Gill, Morton S Kahlenberg, Suresh Nair, Anthony F Shield, Balkrishna N Jahagirdar, Sawyer B Jacobson, Nathan R Foster, Michael N Pollak, Steven R Alberts,

<h4>Background</h4>Adipocyte-derived adiponectin may play a role in the host inflammatory response to cancer. We examined the association of plasma adiponectin with the density of tumor-infiltrating lymphocytes (TILs) in colon cancers and with vitamin D, clinicopathological features, and patient survival.<h4>Methods</h4>Plasma adiponectin and 25-hydroxyvitamin D [25(OH)D] were analyzed by radioimmunoassay in 600 ... Read more >>

JNCI Cancer Spectr (JNCI cancer spectrum)
[2021, 5(5):pkab070]

Cited: 0 times

View full text PDF listing >>



Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer.

Jingyuan Wang, Joanne Xiu, Yasmine Baca, Francesca Battaglin, Hiroyuki Arai, Natsuko Kawanishi, Shivani Soni, Wu Zhang, Joshua Millstein, Bodour Salhia, Richard M Goldberg, Philip A Philip, Andreas Seeber, Jimmy J Hwang, Anthony F Shields, John L Marshall, Igor Astsaturov, A Craig Lockhart, Zoran Gatalica, W Michael Korn, Heinz-Josef Lenz,

Frequent mutations of genes in the histone-lysine N-methyltransferase 2 (KMT2) family members were identified in gastric cancers (GCs). Understanding how gene mutations of KMT2 family affect cancer progression and tumor immune microenvironment may provide new treatment strategies. A total of 1245 GCs were analyzed using next-generation sequencing, whole transcriptome sequencing, ... Read more >>

Oncogene (Oncogene)
[2021, 40(30):4894-4905]

Cited: 1 time

View full text PDF listing >>



Genetically Predicted Circulating C-Reactive Protein Concentration and Colorectal Cancer Survival: A Mendelian Randomization Consortium Study.

Xinwei Hua, James Y Dai, Sara Lindström, Tabitha A Harrison, Yi Lin, Steven R Alberts, Elizabeth Alwers, Sonja I Berndt, Hermann Brenner, Daniel D Buchanan, Peter T Campbell, Graham Casey, Jenny Chang-Claude, Steven Gallinger, Graham G Giles, Richard M Goldberg, Marc J Gunter, Michael Hoffmeister, Mark A Jenkins, Amit D Joshi, Wenjie Ma, Roger L Milne, Neil Murphy, Rish K Pai, Lori C Sakoda, Robert E Schoen, Qian Shi, Martha L Slattery, Mingyang Song, Emily White, Loic Le Marchand, Andrew T Chan, Ulrike Peters, Polly A Newcomb,

<h4>Background</h4>A positive association between circulating C-reactive protein (CRP) and colorectal cancer survival was reported in observational studies, which are susceptible to unmeasured confounding and reverse causality. We used a Mendelian randomization approach to evaluate the association between genetically predicted CRP concentrations and colorectal cancer-specific survival.<h4>Methods</h4>We used individual-level data for 16,918 ... Read more >>

Cancer Epidemiol Biomarkers Prev (Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology)
[2021, 30(7):1349-1358]

Cited: 1 time

View full text PDF listing >>



Prospective Statewide Study of Universal Screening for Hereditary Colorectal Cancer: The Ohio Colorectal Cancer Prevention Initiative.

Rachel Pearlman, Wendy L Frankel, Benjamin J Swanson, Dan Jones, Weiqiang Zhao, Ahmet Yilmaz, Kristin Miller, Jason Bacher, Christopher Bigley, Lori Nelsen, Paul J Goodfellow, Richard M Goldberg, Electra Paskett, Peter G Shields, Jo L Freudenheim, Peter P Stanich, Ilene Lattimer, Mark Arnold, Thomas W Prior, Mitchell Haut, Matthew F Kalady, Brandie Heald, Ian Paquette, David J Draper, Joanna M Brell, Sameer Mahesh, Kisa Weeman, Shyamal Bastola, Jeffrey Zangmeister, Aruna Gowda, Filix Kencana, Albert Malcolm, Yinong Liu, Sharon Cole, Charles Bane, Chaoyang Li, Esther Rehmus, Colin C Pritchard, Brian H Shirts, Angela Jacobson, Shelly A Cummings, Albert de la Chapelle, Heather Hampel,

Hereditary cancer syndromes infer high cancer risks and require intensive surveillance. Identification of high-risk individuals among patients with colorectal cancer (CRC) needs improvement.<h4>Methods</h4>Three thousand three hundred ten unselected adults who underwent surgical resection for primary invasive CRC were prospectively accrued from 51 hospitals across Ohio between January 1, 2013, and ... Read more >>

JCO Precis Oncol (JCO precision oncology)
[2021, 5:]

Cited: 0 times

View full text PDF listing >>



Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database.

Anna D Wagner, Axel Grothey, Thierry Andre, Jesse G Dixon, Norman Wolmark, Daniel G Haller, Carmen J Allegra, Aimery de Gramont, Eric VanCutsem, Steven R Alberts, Thomas J George, Michael J O'Connell, Christopher Twelves, Julien Taieb, Leonard B Saltz, Charles D Blanke, Edoardo Francini, Rachel Kerr, Greg Yothers, Jean F Seitz, Silvia Marsoni, Richard M Goldberg, Qian Shi,

<h4>Background</h4>Adjuvant chemotherapy is a standard treatment option for patients with stage III and high-risk stage II colon cancer. Sex is one of several factors responsible for the wide inter-patient variability in drug responses. Amalgamated data on the effect of sex on the toxicity of current standard adjuvant treatment for colorectal ... Read more >>

J Natl Cancer Inst (Journal of the National Cancer Institute)
[2021, 113(4):400-407]

Cited: 9 times

View full text PDF listing >>



The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer.

Hiroyuki Arai, Andrew Elliott, Joanne Xiu, Jingyuan Wang, Francesca Battaglin, Natsuko Kawanishi, Shivani Soni, Wu Zhang, Joshua Millstein, Davendra Sohal, Richard M Goldberg, Michael J Hall, Aaron J Scott, Moh'd Khushman, Jimmy J Hwang, Emil Lou, Benjamin A Weinberg, John L Marshall, Albert C Lockhart, Phillip Stafford, Jian Zhang, Roberto Moretto, Chiara Cremolini, W Michael Korn, Heinz-Josef Lenz,

<h4>Purpose</h4>Defective DNA damage response (DDR) is a hallmark of cancer leading to genomic instability and is associated with chemosensitivity. Although the mismatch repair system has been extensively studied, the clinical implications of other mechanisms associated with DDR alterations in patients with colorectal cancer remain unclear. This study aimed to understand ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, 27(11):3234-3242]

Cited: 2 times

View full text PDF listing >>



Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial.

Jeffrey A Meyerhardt, Qian Shi, Charles S Fuchs, Jeffrey Meyer, Donna Niedzwiecki, Tyler Zemla, Priya Kumthekar, Katherine A Guthrie, Felix Couture, Philip Kuebler, Johanna C Bendell, Pankaj Kumar, Dequincy Lewis, Benjamin Tan, Monica Bertagnolli, Axel Grothey, Howard S Hochster, Richard M Goldberg, Alan Venook, Charles Blanke, Eileen M O'Reilly, Anthony F Shields,

<h4>Importance</h4>Aspirin and cyclooxygenase 2 (COX-2) inhibitors have been associated with a reduced risk of colorectal polyps and cancer in observational and randomized studies. The effect of celecoxib, a COX-2 inhibitor, as treatment for nonmetastatic colon cancer is unknown.<h4>Objective</h4>To determine if the addition of celecoxib to adjuvant chemotherapy with fluorouracil, leucovorin, ... Read more >>

JAMA (JAMA)
[2021, 325(13):1277-1286]

Cited: 3 times

View full text PDF listing >>



Status of the Clinician Investigator in America: An Essential Healthcare Provider Driving Advances in Cancer Care.

Randall F Holcombe, Claire F Verschraegen, Andrew E Chapman, David Gaffney, Richard M Goldberg, Ruben A Mesa, Mohammed Milhem, Martha Mims, Edith P Mitchell, Dan Mulkerin, Srinivasan Vijayakumar,

<h4>Background</h4>Translation of basic discoveries to clinical care for patients with cancer is a difficult process greatly enabled by physician-trained researchers. Three categories of physicians, with responsibilities spanning from laboratory and preclinical research to direct patient care, are involved in the translational research continuum: physician-scientist (PS), clinician investigator (CI), and academic ... Read more >>

J Natl Compr Canc Netw (Journal of the National Comprehensive Cancer Network : JNCCN)
[2021, 19(2):122-125]

Cited: 0 times

View full text PDF listing >>



Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials.

Frank A Sinicrope, Sakti Chakrabarti, Pierre Laurent-Puig, Luke Huebner, Thomas C Smyrk, Josep Tabernero, Enrico Mini, Richard M Goldberg, Aziz Zaanan, Gunnar Folprecht, Jean Luc Van Laethem, Karine Le Malicot, Qian Shi, Steven R Alberts, Julien Taieb,

<h4>Background</h4>Stratification of patients with stage III colon cancer into low (T<sub>1-3</sub>N<sub>1</sub>) and high (T<sub>4</sub> and/or N<sub>2</sub>) risk groups is used to guide the duration of adjuvant chemotherapy. We determined the relative contribution of clinical and molecular features to survival by risk group.<h4>Materials & methods</h4>Stage III colon cancer (N = 5337) patients from ... Read more >>

Eur J Cancer (European journal of cancer (Oxford, England : 1990))
[2021, 144:101-112]

Cited: 1 time

View full text PDF listing >>



Diagnosis of digestive system tumours.

Mary Kay Washington, Richard M Goldberg, George J Chang, Paul Limburg, Alfred K Lam, Manuel Salto-Tellez, Mark J Arends, Iris D Nagtegaal, David S Klimstra, Massimo Rugge, Peter Schirmacher, Alexander J Lazar, Robert D Odze, Fatima Carneiro, Masashi Fukayama, Ian A Cree, ,

The WHO Classification of Tumours provides the international standards for the classification and diagnosis of tumours. It enables direct comparisons to be made between different countries. In the new fifth edition, the series has gone digital with the launch of a website as well as a series of books, known ... Read more >>

Int J Cancer (International journal of cancer)
[2021, 148(5):1040-1050]

Cited: 3 times

View full text PDF listing >>



Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer.

Christopher Mackintosh, Chen Yuan, Fang-Shu Ou, Sui Zhang, Donna Niedzwiecki, I-Wen Chang, Bert H O'Neil, Brian C Mullen, Heinz-Josef Lenz, Charles D Blanke, Alan P Venook, Robert J Mayer, Charles S Fuchs, Federico Innocenti, Andrew B Nixon, Richard M Goldberg, Eileen M O'Reilly, Jeffrey A Meyerhardt, Kimmie Ng,

<h4>Importance</h4>Several compounds found in coffee possess antioxidant, anti-inflammatory, and insulin-sensitizing effects, which may contribute to anticancer activity. Epidemiological studies have identified associations between increased coffee consumption and decreased recurrence and mortality of colorectal cancer. The association between coffee consumption and survival in patients with advanced or metastatic colorectal cancer is ... Read more >>

JAMA Oncol (JAMA oncology)
[2020, 6(11):1713-1721]

Cited: 4 times

View full text PDF listing >>



Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance).

Julia D Labadie, Xinwei Hua, Tabitha A Harrison, Barbara L Banbury, Jeroen R Huyghe, Wei Sun, Qian Shi, Greg Yothers, Steven R Alberts, Frank A Sinicrope, Richard M Goldberg, Thomas J George, Kathryn L Penney, Amanda I Phipps, Stacey A Cohen, Ulrike Peters, Andrew T Chan, Polly A Newcomb,

<h4>Background</h4>Cetuximab, an EGFR inhibitor used to treat multiple cancer types, including colon cancer, causes severe skin toxicity in 5%-20% of patients, leading to decreased quality of life and treatment delays. Our understanding of which patients have an increased risk of severe toxicities is limited. We conducted a genome-wide association study ... Read more >>

Cancer Epidemiol Biomarkers Prev (Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology)
[2021, 30(2):404-411]

Cited: 0 times

View full text PDF listing >>



The impact of ARID1A mutation on molecular characteristics in colorectal cancer.

Ryuma Tokunaga, Joanne Xiu, Richard M Goldberg, Philip A Philip, Andreas Seeber, Francesca Battaglin, Hiroyuki Arai, Jae Ho Lo, Madiha Naseem, Alberto Puccini, Martin D Berger, Shivani Soni, Wu Zhang, Sting Chen, Jimmy J Hwang, Anthony F Shields, John L Marshall, Hideo Baba, W Michael Korn, Heinz-Josef Lenz,

<h4>Background</h4>ARID1A is a key subunit of the SWItch/Sucrose Non-Fermentable (SWI/SNF) complex which regulates dynamic repositioning of nucleosomes to repair DNA damage. Only small pilot studies have evaluated the role of ARID1A mutation in colorectal cancer (CRC). The aim of the present study was to explore the potential impact of ARID1A ... Read more >>

Eur J Cancer (European journal of cancer (Oxford, England : 1990))
[2020, 140:119-129]

Cited: 4 times

View full text PDF listing >>



Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma.

Andreas Seeber, Kai Zimmer, Florian Kocher, Alberto Puccini, Joanne Xiu, Chadi Nabhan, Andrew Elliott, Richard M Goldberg, Axel Grothey, Anthony F Shields, Francesca Battaglin, Wafik S El-Deiry, Philip A Philip, John L Marshall, Michael Hall, W Michael Korn, Heinz-Josef Lenz, Dominik Wolf, Clemens Feistritzer, Gilbert Spizzo,

<h4>Introduction</h4>Poly-(ADP)-ribose polymerase (PARP) inhibitors are successfully used for treatment of <i>BRCA-</i>mutated (mut) breast cancers and are under extensive evaluation for <i>BRCA-</i> and <i>PALB2-</i>mutated pancreatic ductal adenocarcinoma (PDAC). However, the optimal treatment regimen for <i>BRCA/PALB2</i>-mutated PDCA has yet to be established. Moreover, limited data are available on the association of <i>BRCA/PALB2</i> ... Read more >>

ESMO Open (ESMO open)
[2020, 5(6):e000942]

Cited: 4 times

View full text PDF listing >>



Association of Diet Quality With Survival Among People With Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial.

Erin L Van Blarigan, Sui Zhang, Fang-Shu Ou, Alan Venlo, Kimmie Ng, Chloe Atreya, Katherine Van Loon, Donna Niedzwiecki, Edward Giovannucci, Eric G Wolfe, Heinz-Josef Lenz, Federico Innocenti, Bert H O'Neil, James E Shaw, Blase N Polite, Howard S Hochster, James N Atkins, Richard M Goldberg, Robert J Mayer, Charles D Blanke, Eileen M O'Reilly, Charles S Fuchs, Jeffrey A Meyerhardt,

<h4>Importance</h4>Diet has been associated with survival in patients with stage I to III colorectal cancer, but data on patients with metastatic colorectal cancer are limited.<h4>Objective</h4>To examine the association between diet quality and overall survival among individuals with metastatic colorectal cancer.<h4>Design, setting, and participants</h4>This was a prospective cohort study of patients ... Read more >>

JAMA Netw Open (JAMA network open)
[2020, 3(10):e2023500]

Cited: 0 times

View full text PDF listing >>



Adverse event load, onset, and maximum grade: A novel method of reporting adverse events in cancer clinical trials.

Guilherme S Lopes, Christophe Tournigand, Curtis L Olswold, Romain Cohen, Emmanuelle Kempf, Leonard Saltz, Richard M Goldberg, Herbert Hurwitz, Charles Fuchs, Aimery de Gramont, Qian Shi,

<h4>Background</h4>Current adverse event reporting practices do not document longitudinal characteristics of adverse effects, and alternative methods are not easily interpretable and have not been employed by clinical trials. Introducing time parameters in the evaluation of safety that are comprehensive yet easily interpretable could allow for a better understanding of treatment ... Read more >>

Clin Trials (Clinical trials (London, England))
[2021, 18(1):51-60]

Cited: 0 times

View full text PDF listing >>



Molecular Characterization of Appendiceal Goblet Cell Carcinoid.

Hiroyuki Arai, Yasmine Baca, Francesca Battaglin, Natsuko Kawanishi, Jingyuan Wang, Shivani Soni, Wu Zhang, Joshua Millstein, Curtis Johnston, Richard M Goldberg, Philip A Philip, Andreas Seeber, Joanne Xiu, Jimmy J Hwang, Anthony F Shields, John L Marshall, W Michael Korn, Heinz-Josef Lenz,

Goblet cell carcinoid (GCC) is a distinct subtype of appendiceal neoplasm that exhibits unique clinical and pathologic features. We aimed to reveal the molecular profiles of GCC compared with other appendiceal tumors, such as adenocarcinomas and neuroendocrine tumors. A total of 495 appendiceal tumor samples (53 GCCs, 428 adenocarcinomas, and ... Read more >>

Mol Cancer Ther (Molecular cancer therapeutics)
[2020, 19(12):2634-2640]

Cited: 1 time

View full text PDF listing >>



IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405.

Brendan J Guercio, Sui Zhang, Fang-Shu Ou, Alan P Venook, Donna Niedzwiecki, Heinz-Josef Lenz, Federico Innocenti, Michael N Pollak, Andrew B Nixon, Brian C Mullen, Bert H O'Neil, James E Shaw, Blase N Polite, Al Bowen Benson, James N Atkins, Richard M Goldberg, Justin C Brown, Eileen M O'Reilly, Robert J Mayer, Charles D Blanke, Charles S Fuchs, Jeffrey A Meyerhardt,

<h4>Background</h4>Energy balance-related biomarkers are associated with risk and prognosis of various malignancies. Their relationship to survival in metastatic colorectal cancer (mCRC) requires further study.<h4>Methods</h4>Baseline plasma insulin-like growth factor (IGF)-1, IGF-binding protein (IGFBP)-3, IGFBP-7, C-peptide, and adiponectin were measured at time of trial registration in a prospective cohort of patients with ... Read more >>

JNCI Cancer Spectr (JNCI cancer spectrum)
[2021, 5(1):pkaa074]

Cited: 2 times

View full text PDF listing >>



Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs).

Alberto Puccini, Kelsey Poorman, Mohamed E Salem, Davide Soldato, Andreas Seeber, Richard M Goldberg, Anthony F Shields, Joanne Xiu, Francesca Battaglin, Martin D Berger, Ryuma Tokunaga, Madiha Naseem, Afsaneh Barzi, Syma Iqbal, Wu Zhang, Shivani Soni, Jimmy J Hwang, Philip A Philip, Stefania Sciallero, W Michael Korn, John L Marshall, Heinz-Josef Lenz,

<h4>Purpose</h4>GEP-NENs are rare malignancies with increasing incidence. Their molecular characteristics are still undefined. We explored the underlying biology of GEP-NENs and the differences between gastrointestinal (GI) and pancreatic (PNEN), high-grade (HG), and low-grade (LG) tumors.<h4>Experimental design</h4>GEP-NENs were analyzed using next-generation sequencing (NGS; MiSeq on 47 genes, NextSeq on 592 genes), ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2020, 26(22):5943-5951]

Cited: 6 times

View full text PDF listing >>



Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib.

Yingmiao Liu, Jing Lyu, Kirsten Bell Burdett, Alexander B Sibley, Ace J Hatch, Mark D Starr, John C Brady, Kelli Hammond, Federica Marmorino, Daniele Rossini, Richard M Goldberg, Alfredo Falcone, Chiara Cremolini, Kouros Owzar, Anastasia Ivanova, Dominic T Moore, Michael S Lee, Hanna K Sanoff, Federico Innocenti, Andrew B Nixon,

Regorafenib is a tyrosine kinase inhibitor approved by the FDA for the treatment of patients with chemotherapy refractory metastatic colorectal cancer (mCRC). Regorafenib inhibits signaling through multiple receptors associated with angiogenesis, metastasis, and tumor immunity. Here, we report biomarker results from LCCC1029, a randomized, placebo-controlled, phase II trial of chemotherapy ... Read more >>

Mol Cancer Ther (Molecular cancer therapeutics)
[2020, 19(10):2146-2154]

Cited: 3 times

View full text PDF listing >>



Advertisement


Disclaimer

1.3877 s